A large cohort study drawn from the national IVF registry of France, which included almost 70,000 pregnancies delivered after 22 weeks gestation between 2013 and 2018, has found a higher risk of pre-eclampsia and hypertension in pregnancies derived from frozen-thawed embryos. This risk was found significantly greater in those treatments in which the uterus was prepared for implantation with hormone replacement therapies. The results confirm with real-life data what has been observed in sub-groups of patients in other studies.
The results are presented today by Dr. Sylvie Epelboin from the Hôpital Bichat-Claude Bernard, Paris, at the online annual meeting of ESHRE. The study was performed on behalf of the Mother & child health after ART network, of the French Biomedecine Agency. She said that the results highlight two important considerations in IVF: the potentially harmful effects on vascular pathologies of high and prolonged doses of hormone replacement therapies used to prepare the uterus for the implantation of frozen-thawed embryos; and the protective effect of a corpus luteum, which is present in natural or stimulated cycles for embryo transfer. The hormone replacement therapy given to prepare the uterus for embryo transfer, explained Dr. Epelboin, suppresses ovulation and therefore the formation of the corpus luteum.
The risk of pre-eclampsia and other pregnancy-related disorders of pregnancy has been raised in a growing number of studies of freezing in IVF. However, the overall risks of maternal morbidity are known to be generally lower in pregnancies resulting from frozen embryo transfer than in those from fresh transfers—except in relation to the risk of pre-eclampsia. While some studies have observed such risks in frozen embryo transfers, few studies, said Dr. Epelboin, have compared these “maternal vascular morbidities with the two hormonal environments that preside over the early stages of embryonic development”.
This study divided the cohort of pregnancies from IVF and ICSI in the French national database into three groups of singletons for comparison: those derived from frozen embryo transfer in a natural “ovulatory” cycle (whether stimulated or not) (n = 9,500); those from frozen embryo transfer with hormone replacement therapy (n = 10,373); and conventional fresh transfers (n = 48,152).
Results showed a higher rate of pre-eclampsia with frozen embryos transferred in the artificial (ie, prepared with hormone therapy) frozen cycle (5.3%) than in an ovulatory cycle (2.3%) or in fresh cycles (2.4%). The rates were found similarly distinct in pregnancy-induced hypertension (4.7% vs 3.4% vs 3.3%). These differences were statistically significant, even after adjusting for maternal characteristics (age, parity, tobacco, obesity, history of diabetes, hypertension, endometriosis, polycystic ovaries, premature ovarian failure) to avoid bias.
Dr. Epelboin and colleagues concluded that the study demonstrates that preparation of the uterus with hormones in an artificial cycle is significantly associated with a higher risk of vascular disorders than from cycles with preserved ovulation and fresh embryo transfers.
The use of frozen embryos has increased in IVF in recent years. Success rates in frozen-thawed embryo transfers are reported to be as or more successful than with fresh embryos and, because frozen transfers appear to reduce the risk of hyperstimulation, it also has safety advantages; the blood pressure risks observed in this study and others do not appear to outweigh these benefits, said Dr. Epelboin.
Source: Read Full Article